Published in J Pharmacol Exp Ther on November 01, 1990
5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A (1998) 1.61
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors. Prog Neurobiol (2015) 1.06
Impact of RNA editing on functions of the serotonin 2C receptor in vivo. Front Neurosci (2010) 1.01
Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther (2010) 1.00
The external globus pallidus: progress and perspectives. Eur J Neurosci (2016) 0.89
A new approach for studying GPCR dimers: drug-induced inactivation and reactivation to reveal GPCR dimer function in vitro, in primary culture, and in vivo. Pharmacol Ther (2011) 0.87
Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Br J Pharmacol (1995) 0.85
MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus. Neuropharmacology (2012) 0.85
Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience (2006) 0.84
Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol (1992) 0.83
Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas. Pharmacol Biochem Behav (2005) 0.81
Multiple conformations of 5-HT2A and 5-HT 2C receptors in rat brain: an autoradiographic study with [125I](±)DOI. Exp Brain Res (2013) 0.80
Blockade of motion- and cisplatin-induced emesis by a 5-HT2 receptor agonist in Suncus murinus. Br J Pharmacol (1995) 0.79
Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens. Psychopharmacology (Berl) (2013) 0.77
Regulation of 5-HT2A/C receptors and DOI-induced behaviors by protein kinase Cgamma. Pharmacol Biochem Behav (2006) 0.77
Sustained treatment with a 5-HT(2A) receptor agonist causes functional desensitization and reductions in agonist-labeled 5-HT(2A) receptors despite increases in receptor protein levels in rats. Neuropharmacology (2008) 0.75
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol (1999) 5.83
Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol (1988) 4.25
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci (1995) 3.04
CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens. Neurology (2001) 2.88
Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A (1995) 2.70
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J Biol Chem (1986) 2.03
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1988) 1.86
Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci (1985) 1.77
Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr (1989) 1.75
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci (1984) 1.73
CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology (1995) 1.73
Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature (1995) 1.71
Epidermal growth factor. Physical and chemical properties. J Biol Chem (1972) 1.69
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav (1997) 1.64
Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther (1999) 1.60
Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J Med Chem (1999) 1.53
Synthesis of (3H)DNA complementary to ovalbumin messenger RNA: evidence for limited copies of the ovalbumin gene in chick oviduct. Proc Natl Acad Sci U S A (1973) 1.52
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci (1988) 1.52
Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2013) 1.46
Epidermal growth factor: high and low molecular weight forms. Proc Natl Acad Sci U S A (1970) 1.42
Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav (1987) 1.41
Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci (1996) 1.40
Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology (1990) 1.33
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther (1987) 1.33
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) (1988) 1.31
Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther (1985) 1.29
Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol (1988) 1.29
A potential source of electrophoretic artifacts in polyacrylamide gels. Biochim Biophys Acta (1967) 1.28
Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry (1996) 1.28
The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res (1997) 1.28
The ontogeny of brain receptors for corticotropin-releasing factor and the development of their functional association with adenylate cyclase. J Neurosci (1988) 1.27
Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend (2000) 1.25
Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci (1987) 1.24
Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther (1998) 1.22
A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochem Biophys Res Commun (1987) 1.20
Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol (1990) 1.20
Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis. AIDS Res Hum Retroviruses (1987) 1.19
Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic. Virology (1986) 1.18
Mapping second messenger systems in the brain: differential localizations of adenylate cyclase and protein kinase C. Proc Natl Acad Sci U S A (1986) 1.18
Interleukin 1 receptors in the brain and endocrine tissues. Immunol Today (1993) 1.18
Biologic and immunologic characterization and physical separation of ACTH and ACTH fragments in the ectopic ACTH syndrome. J Clin Invest (1973) 1.17
MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav (1988) 1.17
Physical and chemical properties of Moloney murine leukemia virus p30 protein: a major core structural component exhibiting high helicity and self-association. J Mol Biol (1976) 1.17
Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front Neuroendocrinol (1995) 1.15
Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav (1990) 1.15
Characterization of the binding protein for epidermal growth factor. J Biol Chem (1974) 1.15
Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology (1990) 1.14
Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept (1997) 1.14
Peripheral-type benzodiazepine receptors in endocrine organs: autoradiographic localization in rat pituitary, adrenal, and testis. Endocrinology (1985) 1.14
Purification and properties of clostridiopeptidase B (Clostripain). J Biol Chem (1968) 1.14
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol (1990) 1.13
Nephroblastoma overexpressed gene (NOV) codes for a growth factor that induces protein tyrosine phosphorylation. Gene (1999) 1.13
Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1987) 1.13
ACTH and MSH production by a single cloned mouse pituitary tumor cell line. Endocrinology (1973) 1.11
Application of an objective biological assay of human interferons to clinical specimens and a survey of a normal population. J Clin Microbiol (1985) 1.11
A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther (2000) 1.10
Characterization of the high molecular weight form of epidermal growth factor. J Biol Chem (1974) 1.09
Differences between murine leukemia virus and murine sarcoma virus: effects of virion age and multiplicity of infection on viral RNA. Intervirology (1974) 1.09
Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol (1997) 1.09
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet (1987) 1.09
Central serotonin receptors as targets for drug research. J Med Chem (1987) 1.09
Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol (1996) 1.07
Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? Lancet (1988) 1.07
Corticotropin-releasing factor receptors in rat forebrain: autoradiographic identification. Science (1984) 1.06
Differences between ectopic MSH and pituitary MSH. J Clin Endocrinol Metab (1971) 1.06
Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature (1986) 1.05
Corticotropin-releasing factor receptors in mouse spleen: identification of receptor-bearing cells as resident macrophages. Endocrinology (1990) 1.05
Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections. AIDS (1990) 1.04
5-HT1 and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin. J Med Chem (1990) 1.04
In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J Neurosci (1992) 1.03
14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem (1993) 1.03
Physical properties of moloney murine leukemia virus high-molecular-weight RNA: a two subunit structure. J Virol (1975) 1.03
Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem (1996) 1.03
Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? Bioorg Med Chem (2000) 1.02
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.02
Characteristics and isolation of the phagocytosis-stimulating peptide, tuftsin. Biochim Biophys Acta (1973) 1.02
Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology (1989) 1.01
Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci U S A (1998) 1.01
Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system. Synapse (1987) 0.99
Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) (1998) 0.99
125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Mol Pharmacol (1996) 0.99
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther (2000) 0.99
Discriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse. Psychopharmacology (Berl) (1998) 0.99
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther (1998) 0.99
Studies on the active site of clostripain. The specific inactivation by the chloromethyl ketone derived from -N-tosyl-L-lysine. J Biol Chem (1971) 0.98
High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse (1992) 0.98
Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem Pharmacol (1986) 0.97
Chinese hamster lung cells synthesize and confine to the cellular domain a collagen composed solely of B chains. Proc Natl Acad Sci U S A (1980) 0.97
Progress in the monitoring of human interferon in body fluids and the phenotypic expression of human interferon activity. Prog Clin Pathol (1984) 0.97
Withdrawal from chronic treatment with (+/-)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice. Eur J Pharmacol (1990) 0.95
Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J Neuroimmunol (1996) 0.95
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse (2000) 0.95
Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem (1992) 0.95